300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
Rasco, D.W, Middleton, M.R, Gonzalez, R, Corrie, P, Pavlick, A, Lorigan, P, Plummer, R, Gore, M, Herbert, C, Agarwala, S.S, Logan, T.F, Khleif, S.N, Papadopoulos, K.P, Rangachari, L, Suri, A, Xu, Q, Kneissl, M, Bozón, V, Olszanski, A.J
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article